dorzolamide/timolol
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
122
Go to page
1
2
3
4
5
September 30, 2025
Peripapillary retinoschisis associated with open angle glaucoma responding to dorzolamide.
(PubMed, Retin Cases Brief Rep)
- "We present a case of peripapillary retinoschisis in a phakic patient that developed during treatment with a topical prostaglandin analogue. The schisis resolved after switching the prostaglandin analogue to a topical carbonic anhydrase inhibitor. We suggest that the prostaglandin may have had a role in initiating peripapillary retinoschisis associated with glaucomatous optic neuropathy and that carbonic anhydrase inhibitors are a potential treatment for this condition."
Journal • Glaucoma • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Retinal Disorders
June 14, 2025
Combined procedure with Paul's glaucoma implant and reopening of previous filtering surgery in a patient with hypertensive uveitis crisis and juvenile glaucoma
(SOE 2025)
- "Hypotensive treatment was prescribed with a good response, but 1 week later she presented with the same condition, so oral acetazolamide was added.With the diagnosis of juvenile glaucoma + hypertensive uveitis crisis in the right eye, a complete laboratory work-up was performed with negative serology except for IgG VZV and IgG CMV which was positive...During the postoperative period she presented with hypertensive peaks requiring the following procedures: surgery to unknot the suture + partial removal of the tutor (7th week); complete removal of the tutor in consultation (9th week); topical dorzolamide-timolol and Molteno´s antifibrotic therapy for 6 weeks (3 weeks after removal of the tutor)...The coexistence of pre-existing juvenile glaucoma with an episode of severe, treatment-refractory hypertensive uveitis has not been described as a risk factor. Our hypothesis is that the trabecular meshwork, which has already been altered by juvenile glaucoma, is the target..."
Clinical • Surgery • Glaucoma • Ocular Inflammation • Ophthalmology • Uveitis
June 14, 2025
Cat scratch disease: ocular manifestations
(SOE 2025)
- "Initial therapy was Agapurin, Milgamma, Betaxolol drops and Nurofen...Dexamethasone, Dorzolamide, Timolol and Bromfenac eye drops were added... Cat scratch disease is an infectious illness primarily caused by the bacterium Bartonella henselae, commonly transmitted through scratches or bites from infected cats. While typically characterized by swollen lymph nodes, it can present with diverse range of symptoms. Ocular manifestations can serve as the sole or initial presentation of the disease."
Ophthalmology
June 14, 2025
Improvement of concomitant ocular surface disease in glaucoma patients after switching to a preservative-free fixed combination in a real-world transition context
(SOE 2025)
- "Purpose: To evaluate changes in ocular surface signs and symptoms and their impact on the efficacy of treatment for primary open-angle glaucoma (POAG) in patients with concomitant ocular surface disease (OSD) after switching from a preserved to a preservative-free Dorzolamide 2% + Timolol 0.5% (PF-DT). An experimental, prospective, single-arm, open-label, multicenter trial was conducted... It was demonstrated that switching from a preserved to a PF-DT formulation improved OSD signs and symptoms in patients with POAG, and this strengthened the hypotensive efficacy of the treatment."
Clinical • Real-world • Real-world evidence • Glaucoma • Ophthalmology
June 14, 2025
Hemodialysis and glaucoma (case report)
(SOE 2025)
- "A combined topical β-blocker and carbonic anhydrase inhibitor (Cosopt®) and a prostaglandin analog (Travatan®) were prescribed to both eyes when the intraocular pressure reached 38 and 34 mm Hg in the right and left eyes, respectively. Hemodialysis was performed routinely five times a week for 2 hours and 40 minutes using a central venous catheter. After failure of ocular treatment, glucose was administered intravenously (20% glucose 100 mL/h) during dialysis to prevent an increase in IOP."
Case report • Clinical • Cataract • Glaucoma • Ophthalmology
May 20, 2025
Intraoperative optical coherence tomography in glaucoma surgery with Ex-PRESS® implant.
(PubMed, Eur J Ophthalmol)
- "Our patient was being treated with dorzolamide-timolol eyedrops twice daily and bimatoprost eyedrops once daily in both eyes. I-OCT can help surgeons to locate the correct placement of implants in cases with media opacity (such as corneal opacification or gerontoxon) or in phakic patients, where it is important to avoid lens contact. This instrument is helpful in the training of ophthalmologists."
Journal • Cataract • Glaucoma • Ophthalmology
May 13, 2025
Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
(clinicaltrials.gov)
- P4 | N=70 | Recruiting | Sponsor: Prairie Eye Center | Not yet recruiting ➔ Recruiting
Enrollment open • Glaucoma • Ophthalmology
May 11, 2025
Investigating clues of cystoid macular edema from a vascular perspective under long-term latanoprost usage.
(PubMed, Int Ophthalmol)
- "This study demonstrates that latanoprost, the first prostaglandin analog known for its edema-inducing effect on the macula, does not have a long-term impact on macular vascularity. However, this result should be supported with longer and larger studies."
Journal • Glaucoma • Macular Edema • Ophthalmology
April 27, 2025
Drugs for open-angle glaucoma.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • Glaucoma • Ophthalmology
March 28, 2025
Intravitreal Bevacizumab Alone Vs Combined With Topical Timolol-Dorzolamide or Dorzolamide for Diabetic Macular Edema: A Systematic Review and Meta-Analysis.
(PubMed, Clin Ophthalmol)
- "Randomized controlled trials (RCTs) comparing IVB (1.25 mg, monthly) with topical dorzolamide-timolol (twice daily) or dorzolamide alone (twice daily) were included. Concurrent IVB with topical timolol-dorzolamide or dorzolamide alone demonstrated similar efficacy in improving BCVA and CMT in DME patients. However, the IVB+TD combination resulted in a more significant reduction in IOP compared to IVB alone."
Journal • Retrospective data • Review • Diabetes • Diabetic Macular Edema • Metabolic Disorders • Ophthalmology • Retinal Disorders
March 20, 2025
Triple-fixed Combination of Dorzolamide/Timolol/Brimonidine: Efficacy Study in Bolivian Population.
(PubMed, J Curr Glaucoma Pract)
- "Triple-fixed Combination of Dorzolamide/Timolol/Brimonidine: Efficacy Study in Bolivian Population. J Curr Glaucoma Pract 2024;18(4):137-141."
Journal • Glaucoma • Ophthalmology
March 19, 2025
Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
(clinicaltrials.gov)
- P4 | N=70 | Not yet recruiting | Sponsor: Prairie Eye Center
New P4 trial • Glaucoma • Ophthalmology
March 06, 2025
PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)
(clinicaltrials.gov)
- P3 | N=51 | Terminated | Sponsor: Laboratorios Sophia S.A de C.V. | Trial completion date: Jun 2024 ➔ Oct 2024 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2024 ➔ Oct 2024; Sponsor's prerogative since initial purpose for study shifted according to business strategy.
Head-to-Head • Trial completion date • Trial primary completion date • Trial termination • Glaucoma • Ophthalmology
February 06, 2025
Medicare Part D Glaucoma Drug Prescribing Patterns by Ophthalmologists from 2018 to 2022.
(PubMed, J Ocul Pharmacol Ther)
- "Prostaglandin analogues were the most frequently prescribed class, and the most commonly prescribed drugs were latanoprost, timolol, and the dorzolamide/timolol combination. An increasing number of claims annually, with the exception of the COVID-19 pandemic onset, reflects the growing prevalence of glaucoma. The utilization of new glaucoma agents, such as rho kinase inhibitors, is rapidly increasing as a new therapeutic option."
Journal • Medicare • Reimbursement • US reimbursement • Glaucoma • Infectious Disease • Novel Coronavirus Disease • Ophthalmology
January 28, 2025
Polydipsia Induced Acute Angle-Closure Crisis.
(PubMed, J Glaucoma)
- "He started topical brimonidine, dorzolamide 2%/timolol 0.5%, and latanoprost, and underwent phacoemulsification with placement of a posterior chamber intraocular lens (PCIOL) in the right eye. Several mechanisms of polydipsia induced AACC are proposed including choroidal expansion, increased sympathetic α-adrenergic tone, or differences in osmotic potential forces."
Journal • Cardiovascular • Heart Failure • Ophthalmology • Pain
January 26, 2025
Development and Evaluation of Polymethacrylate-Based Ophthalmic Nanofiber Inserts Containing Dual Drug-Loaded Dorzolamide and Timolol: In Vivo Study in Rabbit's Eye.
(PubMed, Biomedicines)
- "The cell compatibility test showed a high percentage of cell survival, and none of the formulations irritated the rabbit's eye. The Area Under the Curve (AUC0-72) for DOR and TIM in EDT formulations was approximately 3216.63 ± 63.25 µg·h/mL and 2598.89 ± 46.65 µg·h/mL, respectively, with Mean Residence Times (MRTs) of approximately 21.6 ± 0.19 h and 16.29 ± 6.44 h. Based on the results, the dual drug-loaded nanofiber preservative-free system can potentially be a suitable alternative to eye drops and can be used to reduce fluctuation and dose frequency."
Journal • Preclinical • Glaucoma • Ophthalmology
January 22, 2025
Simultaneous central retinal vein and cilioretinal artery occlusion in a young female patient with progestin-only oral contraceptive use: a case report.
(PubMed, J Med Case Rep)
- "This case highlights the rare presentation of simultaneous central retinal vein occlusion and cilioretinal artery occlusion, likely precipitated by short-term progestin-only OCP use in a young female. The absence of other vascular risk factors emphasizes the potential thrombotic risk associated with hormonal contraception, even in brief courses. Careful consideration should be given to contraceptive choice, and ophthalmologic monitoring is recommended for early detection and intervention in at-risk patients."
Journal • Cardiovascular • Hematological Disorders • Ophthalmology • Pain • Retinal Disorders • Venous Thromboembolism
January 21, 2025
Efficacy and safety of preservative-free anti-glaucomatous eye drops (dorzolamide/timolol) in ocular hypertension and/or glaucoma.
(PubMed, Int Ophthalmol)
- "Generally, the PF dorzolamide/timolol combination was associated with a significant reduction in IOP and tolerability among glaucoma patients."
Journal • Cardiovascular • Glaucoma • Ophthalmology
December 18, 2024
Randomized Clinical Trial of Intraocular Pressure-Lowering Medications on Preventing Spikes in Intraocular Pressure Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
(PubMed, Ophthalmol Ther)
- "Topical fixed combination anti-glaucoma medication used as a prophylactic treatment before intravitreal anti-VEGF injections significantly prevented IOP spikes post-injection, with a comparable effect among three medications. Prophylactic treatment of IOP spikes should be considered as standard care to prevent further damage in patients with compromised retinal vascular and optic nerve perfusion."
Clinical • Journal • Allergy • Glaucoma • Immunology • Ophthalmology • Retinal Disorders
December 16, 2024
Efficacy and Safety of a Fixed-Dose Combination of Brinzolamide 1%/Timolol 0.5% vs. Dorzolamide 2%/Timolol 0.5% in Indian Patients With Primary Open-Angle Glaucoma or Ocular Hypertension: A Randomized Phase 3 Study.
(PubMed, Cureus)
- "Fewer subjects in FDC brinzolamide/timolol group experienced ocular AEs as compared with FDC dorzolamide/timolol group (9.9% vs. 26.4%), especially ocular hyperemia (2.7% vs. 22.7%). Conclusion FDC of brinzolamide 1%/timolol 0.5% affords an ocular comfort advantage with a clinically meaningful reduction in IOP that was non-inferior to FDC of dorzolamide 2%/timolol 0.5% in Indian patients with POAG and ocular hypertension."
Journal • P3 data • Cardiovascular • Glaucoma • Ophthalmology
November 21, 2024
Approaches for improvement of ocular surface condition in primary open-angle glaucoma
(PubMed, Vestn Oftalmol)
- "In patients with POAG, DES, and MGD who are undergoing therapy with BAC-containing medications, an approach involving switching to BAC-free eye drops combined with eyelid hygiene (using "Blepharogel cleansing", "Blepharolotion", and "Blepharogel-1") proved to be more effective than the approach of switching to BAC-free medications without additional eyelid hygiene."
Clinical • Journal • Dry Eye Disease • Glaucoma • Ophthalmology
November 21, 2024
Efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol) in primary open-angle glaucoma
(PubMed, Vestn Oftalmol)
- "This study confirms the high hypotensive efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol)."
Journal • Glaucoma • Ophthalmology
November 06, 2024
Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety
(clinicaltrials.gov)
- P4 | N=84 | Completed | Sponsor: Laboratorios Poen | Recruiting ➔ Completed
Trial completion • Cardiovascular • Glaucoma • Ophthalmology
October 28, 2024
Conjunctival Collagen Cross-Linking for the Treatment of Leaking Avascular Cystic Bleb.
(PubMed, Turk J Ophthalmol)
- "Here, we present the case of a 70-year-old male patient with a leaking avascular cystic bleb. Following treatment with a combination of conjunctival CCL, topical gentamicin, a dorzolamide/timolol combination, and a therapeutic contact lens, the patient experienced cessation of bleb leakage and an increase in IOP."
Journal • Glaucoma • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology
July 28, 2024
Boston Keratoprosthesis Type 1 In A Patient With Bilateral Alkali Burn
(ESCRS 2024)
- "Initially, he was performed an amniotic membrane graft with tyssel on both eyes and used corticoesteroids during 3 weeks, cyclosporine, Loteprednol, moxifloxacin and dorzolamide+ timolol + Brimonidine twice a day for several months, later on a simple limbal epithelial transplantation (SLET) was made, and, ultimately on September 2023, a Boston type 1 Keratoprosthesis was performed without complications. Conclusion/Take home message: Boston Keratoprosthesis type 1 is a great alternative for severe corneal diseases due to limbal stem cell deficiency, corneal neovascularization or corneal edema with a poor prognosis, which can provide a better visual acuity and anatomical retention to the patient."
Clinical • Cataract • Ocular Infections • Ophthalmology
1 to 25
Of
122
Go to page
1
2
3
4
5